Previous close | 4.9000 |
Open | 4.8300 |
Bid | 4.6600 x 400 |
Ask | 4.7300 x 500 |
Day's range | 4.6800 - 4.9200 |
52-week range | 4.2500 - 12.7500 |
Volume | |
Avg. volume | 208,460 |
Market cap | 169.095M |
Beta (5Y monthly) | 0.05 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.4200 |
Earnings date | 14 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 19.50 |
Management to host conference call and webcast at 4:30 p.m. ETBURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, May 14th, 2024, to discuss the financial results
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders might be concerned after seeing the share price drop 23% in the...